CA
NZ
UK
AU
IND
US
…
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing immune-stimulating antibody conjugates that deliver immune-activating payloads to tumors to enhance anti-cancer responses. Its long-term growth drivers include validation of its platform through clinical trials, potential combinations with checkpoint inhibitors, and partnerships to advance development and commercialization, which may benefit from rising demand for targeted oncology therapies.
Principal investment risks include clinical and regulatory outcome uncertainty, ongoing financing requirements, manufacturing and safety challenges specific to conjugate therapies, and strong competition from established oncology developers.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -33.38M | -63.12M | -69.20M | -88.10M | -98.59M |
| Net income | -33.38M | -63.12M | -69.20M | -85.88M | -104.39M |
| Selling general administrative | 13.79M | 18.46M | 22.53M | 22.93M | 18.39M |
| Gross profit | 6.20M | 7.69M | -53.67M | 5.73M | 1.26M |
| Reconciled depreciation | 1.29M | 1.78M | 1.85M | 1.67M | 1.19M |
| Ebit | -34.63M | -68.24M | -76.20M | -90.32M | -92.79M |
| Ebitda | -33.14M | -66.45M | -74.34M | -88.66M | -85.51M |
| Depreciation and amortization | 1.49M | 1.78M | 1.85M | 1.67M | 7.28M |
| Operating income | -34.63M | -73.05M | -76.20M | -90.32M | -92.79M |
| Other operating expenses | 42.33M | 80.74M | 84.07M | 96.05M | 94.05M |
| Interest expense | - | - | - | -2.22M | 5.80M |
| Interest income | 2.50M | 5.25M | 6.18M | 2.22M | 0.28M |
| Net interest income | 2.50M | 5.25M | 6.18M | 2.22M | 0.28M |
| Income tax expense | - | - | 1.72M | -2.22M | 5.80M |
| Total revenue | 7.70M | 7.69M | 7.88M | 5.73M | 1.26M |
| Total operating expenses | 40.84M | 80.74M | 22.53M | 96.05M | 94.05M |
| Cost of revenue | 1.49M | 2.18M | 61.54M | - | - |
| Total other income expense net | 1.26M | 9.93M | 7.00M | 2.22M | -5.80M |
| Net income from continuing ops | -33.38M | -63.12M | -71.29M | -88.10M | -98.59M |
| Net income applicable to common shares | - | - | - | -88.10M | -98.59M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 56.75M | 99.63M | 159.78M | 227.81M | 307.72M |
| Other current assets | 1.78M | 2.33M | 2.04M | 3.86M | 2.94M |
| Total liab | 30.24M | 42.43M | 47.04M | 56.30M | 57.60M |
| Total stockholder equity | 26.50M | 57.20M | 112.74M | 171.51M | 250.12M |
| Other current liab | 3.72M | 9.08M | 12.49M | 15.14M | 12.38M |
| Common stock | - | - | 0.00M | - | -307.72M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -460.78M | -427.40M | -364.29M | -295.09M | -206.99M |
| Other liab | - | - | - | 12.96M | 14.42M |
| Other assets | - | - | 0.00M | 2.59M | 2.61M |
| Cash | 11.70M | 7.21M | 10.81M | 9.24M | 27.38M |
| Total current liabilities | 8.44M | 15.86M | 20.46M | 23.12M | 21.33M |
| Current deferred revenue | 0.45M | 3.02M | 2.20M | 1.99M | 2.87M |
| Net debt | 11.26M | 18.00M | 9.41M | 13.37M | -3.03M |
| Short term debt | 2.83M | 2.25M | 2.78M | 2.39M | 2.50M |
| Short long term debt total | 22.96M | 25.21M | 20.22M | 22.61M | 24.36M |
| Other stockholder equity | 487.31M | 484.50M | 317.20M | 239.71M | 149.71M |
| Property plant equipment | - | - | - | 28.52M | 30.60M |
| Total current assets | 30.26M | 50.81M | 105.53M | 172.75M | 189.16M |
| Long term investments | 4.34M | 22.88M | 26.41M | 23.94M | 85.35M |
| Net tangible assets | - | - | - | 171.51M | 250.12M |
| Short term investments | 15.80M | 40.12M | 91.38M | 159.64M | 158.84M |
| Net receivables | 0.97M | 1.17M | 1.30M | 0.80M | 0.20M |
| Inventory | - | 0.00M | - | - | - |
| Accounts payable | 1.44M | 1.51M | 2.99M | 3.59M | 3.57M |
| Accumulated other comprehensive income | -0.02M | 0.10M | 0.04M | -0.92M | -0.32M |
| Non currrent assets other | 1.68M | 1.04M | 2.00M | 2.59M | 2.61M |
| Non current assets total | 26.49M | 48.82M | 54.25M | 55.06M | 118.56M |
| Capital lease obligations | 22.96M | 25.21M | 20.22M | 22.61M | 24.36M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 43.41M | 57.58M | 71.66M | 57.86M | -232.20M |
| Change to liabilities | - | - | - | 0.61M | 22.25M |
| Total cashflows from investing activities | 44.30M | 57.58M | 71.04M | 57.86M | -232.20M |
| Total cash from financing activities | 0.02M | 0.11M | 0.25M | 0.50M | 311.11M |
| Change to operating activities | - | - | - | -3.66M | -1.74M |
| Net income | -33.38M | -63.12M | -69.20M | -88.10M | -98.59M |
| Change in cash | 4.47M | -3.60M | 1.77M | -18.14M | 21.84M |
| Begin period cash flow | 8.97M | 12.57M | 10.81M | 28.95M | 7.11M |
| End period cash flow | 13.44M | 8.97M | 12.57M | 10.81M | 28.95M |
| Total cash from operating activities | -39.85M | -61.29M | -69.53M | -76.50M | -57.07M |
| Issuance of capital stock | 0.02M | 0.11M | 0.29M | 0.50M | 311.11M |
| Depreciation | 1.29M | 1.78M | 1.85M | 1.67M | 1.19M |
| Other cashflows from investing activities | 0.96M | 0.15M | - | - | - |
| Sale purchase of stock | - | - | - | - | 13.64M |
| Other cashflows from financing activities | 0.02M | 0.11M | 71.04M | 57.86M | 38.26M |
| Change to netincome | - | - | - | - | 19.82M |
| Capital expenditures | 0.07M | 0.04M | 0.21M | 1.95M | 2.34M |
| Change in working capital | -12.12M | -8.44M | -9.86M | -3.06M | 20.51M |
| Stock based compensation | 2.78M | 7.41M | 9.22M | 9.58M | 8.50M |
| Other non cash items | 1.57M | 1.08M | -1.54M | 3.41M | 8.56M |
| Free cash flow | -39.92M | -61.33M | -69.73M | -78.46M | -59.40M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BOLT Bolt Biotherapeutics |
0.23 3.62% |
6.59 | - | - | 1.29 | 0.36 | 0.66 | 0.93 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
900 Chesapeake Drive, Redwood City, CA, United States, 94063
650 665 9295
23
| Name | Title | Year Born |
|---|---|---|
| Dr. Randall C. Schatzman Ph.D. | CEO & Director | 1955 |
| Dr. Edgar G. Engleman M.D. | Founder & Independent Director | 1946 |
| Mr. William P. Quinn | CFO & Sec. | 1971 |
| Mr. Grant Yonehiro C.F.A., M.B.A. | Chief Bus. Officer | 1964 |
| Dr. Edith A. Perez M.D. | Chief Medical Officer | 1957 |
| Ms. Karen L. Bergman | VP of Communications & Investor Relations | NA |
| Mr. Wesley Burwell | VP & Head of HR | NA |
| Dr. Nathan Ihle Ph.D. | Sr. VP of Pharmaceutical Operations | NA |
| Mr. Bruce Hug M.D., Ph.D. | Sr. VP of Clinical Devel. & Translational Medicine | NA |
| Dr. Ming Yin Ph.D. | VP & Head of Biometrics | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...